Search

Your search keyword '"Codeluppi M"' showing total 246 results

Search Constraints

Start Over You searched for: Author "Codeluppi M" Remove constraint Author: "Codeluppi M"
246 results on '"Codeluppi M"'

Search Results

1. GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial

2. Corrigendum to: “Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study)” Clinical Microbiology and Infection 26 (2020) 1545–1553 (Clinical Microbiology and Infection (2020) 26(11) (1545–1553), (S1198743X20304791), (10.1016/j.cmi.2020.08.003))

5. GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial

7. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

8. The burden of clostridioides difficile infection during the COVID-19 pandemic: A retrospective case-control study in Italian hospitals (CloVid)

9. Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia, A double-blind, randomised, placebo-controlled trial

12. Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9)

17. Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol

29. PS1274 EPIDEMIOLOGY AND MANAGEMENT OF LATENT TUBERCULOSIS INFECTION IN ADULT PATIENTS WITH ACUTE LEUKEMIA OR APLASTIC ANEMIA: A RETROSPECTIVE MONOCENTER STUDY

31. T-cell Interferon-gamma-release assays performance to detect latent tuberculosis infection in immunocompromised patients

32. Longitudinal assessment of pre-transplant mortality risk among HIV-infected and uninfected patients with end-stage liver disease: the role of delta-meld score

35. T-cell Interferon-gamma-release assays performance to detect latent tuberculosis infection in immunocompromised patients

36. Adult liver transplantation in HIV-infected patients

38. Clinical and Microbiological Characteristics of Visceral Leishmaniasis Outbreak in a Northern Italian Nonendemic Area: A Retrospective Observational Study

39. Detection of Pneumocystis jirovecii and Aspergillus spp. DNA in bronchoalveolar lavage fluids by commercial real-time PCR assays: Comparison with conventional diagnostic tests

40. European Confederation of Medical Mycology (ECMM) prospective survey of cryptococcosis: Report from Italy

41. Evaluation of serum (1 → 3)-β-d-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors

50. Different dose adjustments of immunosuppresants are necessary after initiating boosted or unboosted first protease inhibitors regimen post-liver transplantation

Catalog

Books, media, physical & digital resources